<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="151526">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02133989</url>
  </required_header>
  <id_info>
    <org_study_id>2013-06-123</org_study_id>
    <nct_id>NCT02133989</nct_id>
  </id_info>
  <brief_title>Clopidogrel Resistance and Embolism in Carotid Artery Stenting</brief_title>
  <acronym>CRECAS</acronym>
  <official_title>Ticlopidine+Ginkgo Biloba Versus Clopidogrel in Clopidogrel Resistant Patients Undergoing Cartoid Artery Stent Placement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Yuyu Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <authority>South Korea: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of the ticlopidine + ginko
      biloba compared to clopidogrel in clopidogrel resistant patients undergoing carotid artery
      stent placement. The investigators hypothesized that ticlopidine + ginko biloba is superior
      than clopidogrel in terms of post-stent ischemic lesions in these patients without serious
      complications.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>New ischemic lesion on diffusion-weighted imaging (DWI)</measure>
    <time_frame>within 24 hours after carotid stenting</time_frame>
    <safety_issue>No</safety_issue>
    <description>Presence of new ischemic lesion in the ipsilesioinal hemisphere on DWI after carotid stening</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number and Volume of new ischemic lesions on DWI</measure>
    <time_frame>within 24 hours after carotid stenting</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Benign and malignant microembolic signals (MES) on transcranial Doppler (TCD)</measure>
    <time_frame>within 24 hours after carotid stenting</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemic stroke or transient ischemic attack (TIA)</measure>
    <time_frame>within 30 days after carotid stenting</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of clopidogrel resistance</measure>
    <time_frame>1 day after carotid stenting</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change of clopidogrel resistance measured by Verify now (P2Y12)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pucture site hematoma</measure>
    <time_frame>within 30 days after carotid stenting</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mycocardial infarction</measure>
    <time_frame>within 30 days after carotid stenting</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>within 30 days after carotid stenting</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematological abnormalities</measure>
    <time_frame>within 30 days after carotid stenting</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Neutrophil &lt;1500/uL Platelet &lt;100,000/uL AST or ALT &gt;120 U/L</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">86</enrollment>
  <condition>Carotid Stenosis</condition>
  <arm_group>
    <arm_group_label>Ticlopidine+Ginko biloba</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Switch to ticlopidine + ginko biloba</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clopidogrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Keep clopidogrel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticlopidine + Ginko biloba</intervention_name>
    <description>ticlopidine hydrochloride 250mg, ginko leaf ext. 80mg, twice daily</description>
    <arm_group_label>Ticlopidine+Ginko biloba</arm_group_label>
    <other_name>Yuclid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>clopidogrel bisulfate 97.875mg(75mg as clopidogrel)</description>
    <arm_group_label>Clopidogrel</arm_group_label>
    <other_name>Plavix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients scheduled for stent implantation due to carotid stenosis

          -  Patients resistant to clopidogrel defined by platelet inhibition rate &lt;20% measured
             by Verify Now before carotid stenting

          -  Patients with informed consent

        Exclusion Criteria:

          -  Antiplatelet therapy other than aspirin, clopidogrel, or ticlopidine

          -  Unable to perform MRI scans

          -  Patients with hematologic abnormalities including neutrophil &lt;1500/ul, platelet
             &lt;100,000/uL, or AST/ALT &gt;120 U/L

          -  Unsuitable for participation
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oh Young Bang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Oh Young Bang, MD</last_name>
    <phone>82-2-3410-3599</phone>
    <email>neuroboy50@naver.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Suk Jae Kim, MD</last_name>
    <phone>82-2-3410-1895</phone>
    <email>sukjae.kim@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Oh Young Bang</name>
      <address>
        <city>Seoul</city>
        <zip>135710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Oh Young Bang, MD</last_name>
      <phone>82-2-3410-3599</phone>
      <email>neuroboy@unitel.co.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 6, 2014</lastchanged_date>
  <firstreceived_date>April 28, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Oh Young Bang</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Carotid stenosis</keyword>
  <keyword>Stenting</keyword>
  <keyword>Clopidogrel resistance</keyword>
  <keyword>Stroke, ischemic</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carotid Stenosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
